TITLE:
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

CONDITION:
Staphylococcal Skin Infection

INTERVENTION:
Telavancin

SUMMARY:

      Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and
      an approved drug, vancomycin, for the treatment of complicated skin and skin structure
      infections.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients must have a diagnosis of one of the following complicated skin and skin
             structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either
             suspected or confirmed as the major cause of the infection:

               -  major abscess requiring surgical incision and drainage

               -  infected burn (see exclusion criteria for important qualifications)

               -  deep/extensive cellulitis

               -  infected ulcer (see exclusion criteria for important qualifications)

               -  wound infections

          -  Patients must be expected to require at least 7 days of intravenous antibiotic
             treatment

        Exclusion Criteria:

          -  Received more than 24 hours of potentially effective systemic (IV, IM or PO)
             antibiotic therapy prior to randomization

          -  Burns involving > 20% of body surface area or third-degree/full-thickness in nature,
             diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fascitis, gas gangrene, or
             mediastinitis.
      
